Homologes Rekombinationsmangel (HRD)-positives hochgradiges seröses Ovarialkarzinom (B...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-OVARIAN-HRD-POSITIVE-ACTIONABLE |
|---|---|
| Art | Warnhinweis |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Erkrankungen | DIS-OVARIAN |
| Quellen | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-NOVA-MIRZA-2016 SRC-PRIMA-GONZALEZ-MARTIN-2019 |
Ursprung der Roten Flagge
| Begriffsbestimmung | Homologous Recombination Deficiency (HRD)-positive high-grade serous ovarian carcinoma (BRCA1/2 mutation OR Genomic Instability Score ≥42). PARPi maintenance after platinum-based induction is treatment-defining: niraparib (PRIMA — mPFS 21.9 vs 10.4 mo HRD-pos), olaparib + bevacizumab (PAOLA-1 — mPFS 37.2 vs 17.7 mo HRD-pos). |
|---|---|
| Klinische Richtung | Intensivierung |
| Kategorie | high-risk-biology |
| Schaltet Algorithmus | ALGO-OVARIAN-ADVANCED-1L, ALGO-OVARIAN-2L |
Logik auslösen
{
"any_of": [
{
"finding": "hrd_status",
"value": "HRD-positive"
},
{
"finding": "hrd_status",
"value": "positive"
},
{
"comparator": ">=",
"finding": "genomic_instability_score",
"threshold": 42
}
],
"type": "biomarker"
}
Anmerkungen
HRD assays: Myriad myChoice CDx (companion for olaparib + bev, niraparib), FoundationOne CDx HRD. GIS captures BRCAness (LOH + TAI + LST signatures) in tumors WT for BRCA1/2. HRD-negative HGSC has minimal PARPi maintenance benefit (PRIMA mPFS 8.1 vs 5.4 mo) — bev maintenance preferred. Coexists with RF-OVARIAN-BRCA-MUT-ACTIONABLE (BRCA-mut subset is HRD-positive by definition); RF-OVARIAN-HRD-ACTIONABILITY is the older composite version.
Verwendet von
Algorithmen
ALGO-OVARIAN-2L- ALGO-OVARIAN-2LALGO-OVARIAN-ADVANCED-1L- ALGO-OVARIAN-ADVANCED-1L
Kapitel des Handbuchs
HB-OVARIAN-MAINTENANCE-1L- fortgeschrittener Eierstockkrebs: HRD/BRCA First-Line-Wartungshygienische
Handbuchfragen
HQ-OVARIAN-MAINTENANCE-1L-002- HQ-OVARIAN-MAINTENANCE-1L-002